Wells Fargo analyst Tiago Fauth initiated coverage of Ultragenyx with an Overweight rating and $72 price target. The “pipeline optionality” for the company is too great to ignore, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RARE:
- Ultragenyx price target lowered to $126 from $133 at Citi
- Ultragenyx price target lowered to $74 from $76 at JPMorgan
- Ultragenyx to Participate at Investor Conferences in November
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Biotech Alert: Searches spiking for these stocks today